公开(公告)号：US20250066452A1

公开(公告)日：2025-02-27

申请号：US18842535

申请日：2023-03-02

Applicant: UNIVERSITY OF MARYLAND, BALTIMORE ,  The United States of America, As Represented by The Secretary, Department of Health and Human Servi

Inventor： Konstantin BIRUKOV ,  Thomas L. EGGERMAN ,  Alexander V. BOCHAROV ,  Cynthia L. RENN

IPC: C07K14/775 ,  A61K9/06 ,  A61K38/00 ,  A61K45/06 ,  A61P29/00

Abstract: Therapeutic agents, compositions, and methods are described for use in the treatment of acute or chronic pain, neuroinflammation, or conditions characterized by acute or chronic pain or neuroinflanmmation. The therapeutic agents comprise a synthetic amphipathic helical peptide capable of acting as a mimetic of apoA-I protein.

公开(公告)号：US20250064783A1

公开(公告)日：2025-02-27

申请号：US18939776

申请日：2024-11-07

Applicant: Psilera Inc.

Inventor： Christopher G. Witowski ,  Jacqueline L. Salm

IPC: A61K31/4045 ,  A61K9/00 ,  A61K9/06 ,  A61K9/20 ,  A61K9/70 ,  A61K31/405 ,  A61K31/48 ,  A61K31/55 ,  A61K31/675 ,  C07D209/16

Abstract: Pharmaceutical formulations of novel indole compounds and psilocybin analogs are manufactured, provided in novel oral, transdermal, and nasal pharmaceutical compositions for use to treat neurological, mood or abuse diseases and disorders.

公开(公告)号：US20250064730A1

公开(公告)日：2025-02-27

申请号：US18941158

申请日：2024-11-08

Applicant: University of Florida Research Foundation, Inc.

Inventor： Anuj Chauhan ,  Russell Macoon

IPC: A61K9/06 ,  A61K9/00 ,  A61K31/5377 ,  A61K47/10 ,  A61K47/12 ,  A61K47/38 ,  A61K47/44

Abstract: In one aspect, the disclosure relates to compositions for the extended release of drugs in the retina. In a further aspect, the present disclosure provides methods of preparing extended release compositions comprising a therapeutic agent for use in retinal drug delivery. In various other aspects, the present disclosure provides methods for delivery of the disclosed compositions comprising a therapeutic agent to the retina via intravitreal injection. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.

公开(公告)号：US20250057917A1

公开(公告)日：2025-02-20

申请号：US18800237

申请日：2024-08-12

Applicant: Xequel Bio, Inc.

Inventor： Carissa HAYNES ,  Christina L. GREK

IPC: A61K38/17 ,  A61K9/06 ,  A61K47/38 ,  A61P17/02

Abstract: The present disclosure provides compositions and methods for use in treating radiation injury such as a radiation induced skin injury in a subject at risk of such injury. Also provided herein is a reproducible animal model of cutaneous radiation injuries for evaluation of medical countermeasures.

公开(公告)号：US20250057879A1

公开(公告)日：2025-02-20

申请号：US18936726

申请日：2024-11-04

Applicant: NANO MPI HOLDINGS, INC.

Inventor： Marshall WEINGARDEN ,  Lyudmyla DERYMEDVID ,  Wladimir BORODIN ,  Volodymyr IVASHCHENKO ,  Andrey FACTOR

IPC: A61K33/44 ,  A61K9/06 ,  A61K9/14 ,  A61K31/573 ,  A61K36/185 ,  A61P17/02

Abstract: A pharmaceutical composition to treat epidermal insults may have a pharmaceutically effective amount an ultra-dispersed detonation synthesis nanodiamond crystals (DND) and medical grade Siberian Sea Buckthorn Berry Oil (SBB) composition in a blended uniform composition with 1% hydrocortisone cream for use in treating a subject with pemphigus vulgaris. The DND may be at 2 nm to 4 nm in initial crystal size and in the range of 0.2% to 0.5% of the DND-SBB composition weigh and the SBB which is 99.5% to 99.8% of the DND-SBB composition weight. The total composition ratio may be in the range of about 3:1 to 10:1 1% hydrocortisone cream to DND-SBB composition. A method to treat epidermal insults may include the step of applying the composition over an area of skin affected with pemphigus twice daily for 3-6 weeks.

公开(公告)号：US20250057878A1

公开(公告)日：2025-02-20

申请号：US18937758

申请日：2024-11-05

Applicant: CORTICALIS AS

Inventor： Ståle Petter Lyngstadaas ,  Håvard J. Haugen

IPC: A61K33/40 ,  A61K9/06 ,  A61K47/12 ,  A61P31/04

Abstract: The present invention relates to a new multifunctional debridement and/or antifouling composition comprising H2O2 at a final concentration of between 0.1-5% v/v, and a composite hydrogel formulation comprising pluronic acid at a concentration of 10-40% w/v, wherein the composition is in liquid form at room temperature. The composition disclosed herein is antimicrobial and/or anti-inflammatory and is particular useful in periimplantitis treatment and implant health maintenance, in periodontitis and periodontal health and in wound care and chronic ulcer care.

公开(公告)号：US12227598B2

公开(公告)日：2025-02-18

申请号：US18139434

申请日：2023-04-26

Applicant: Bausch & Lomb Incorporated

Inventor： Alok Kumar Awasthi ,  James Anthony DiBella, Jr. ,  Mark R. Mis ,  Alai Musleh ,  George L. Grobe, III

IPC: C08B37/08 ,  A61K9/00 ,  A61K9/06 ,  A61K31/685 ,  A61K31/728 ,  A61L26/00 ,  A61L27/34 ,  G02B1/18

Abstract: A biomedical device having a coating on a surface thereof, where the coating includes a glycophospholipid polymer which is a reaction product of one or more glycosaminoglycans and one or more phospholipids.

公开(公告)号：US12226525B2

公开(公告)日：2025-02-18

申请号：US17133980

申请日：2020-12-24

Applicant: Mati Therapeutics, Inc.

Inventor： Eugene de Juan, Jr. ,  Stephen Boyd ,  Cary J. Reich ,  Alan R. Rapacki ,  Hanson S. Gifford ,  Mark Deem

IPC: A61K9/00 ,  A61F9/00 ,  A61F9/007 ,  A61K9/06 ,  A61K31/215 ,  A61K31/216 ,  A61K31/55 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/573 ,  A61K47/34 ,  A61L31/16

Abstract: An implant for insertion through a punctum and into a canalicular lumen of a patient. The implant includes a matrix of material, a therapeutic agent dispersed in the matrix of material, a sheath disposed over a portion of the matrix of material and configured to inhibit the therapeutic agent from being released from the matrix of material into the canalicular lumen and to allow the therapeutic agent to be released from a surface of the matrix of material to a tear film, and a retention structure configured to retain the implant within the canalicular lumen.

公开(公告)号：US20250041257A1

公开(公告)日：2025-02-06

申请号：US18921791

申请日：2024-10-21

Applicant: InTrance Medical Systems Inc.

Inventor： Roger Bolsöy

IPC: A61K31/198 ,  A61K9/00 ,  A61K9/06 ,  A61K9/16 ,  A61K31/165 ,  A61K31/277 ,  A61K45/06 ,  A61K47/38

Abstract: A pharmaceutical gel composition for intra-intestinal administration comprises (i) a dopamine replacement agents, (ii) a dopamine decarboxylase inhibitor (DDD), and (ii) a COMT inhibitor.

公开(公告)号：US20250032408A1

公开(公告)日：2025-01-30

申请号：US18781571

申请日：2024-07-23

Applicant: Boston Scientific Scimed, Inc.

Inventor： Joseph Thomas Delaney, JR. ,  Cristian Parisi ,  Yen-Hao Hsu ,  Rick Dorn

IPC: A61K9/06 ,  A61K47/34 ,  A61L27/52 ,  C08G65/332 ,  C08G65/333

Abstract: In some aspects, the present disclosure provides reactive polymers that comprise one or more hydrophilic polymer segments having a plurality of hydrophilic polymer segment ends and a plurality of reactive moieties covalently linked to at least a portion of the hydrophilic polymer segment ends. The reactive moieties are 3,4-substituted-2,5-pyrrolidinedione moieties in which the 3-carbon and the 4-carbon form part of at least one ring in addition to the 2,5-pyrrolidinedione ring, and the 2,5-pyrrolidinedione ring nitrogen atom of each of the 3,4-substituted-2,5-pyrrolidinedione moieties is linked to one of the hydrophilic polymer segment ends. In other aspects, the present disclosure provides systems for forming hydrogel compositions and methods of treatment that employ such reactive polymers and methods of synthesizing such reactive polymers.